Domestic first blood glucose management probiotic 'DangQLac' signs overseas sales and distribution agreement

Yuhan Corporation (CEO Cho Wook-jae) signed an agreement with Osang Healthcare (CEO Kang Cheol-hoon, Yoo Byung-ryul), a leading domestic company in the in vitro diagnostics (IVD) field, at Yuhan Corporation's headquarters on the 6th for the global business of DangQLac, the first blood glucose management probiotic in Korea.

The two companies agreed to cooperate on the global business of Yuhan Corporation's DangQLac, and to this end, they signed a “global sales and distribution agreement” granting Osang Healthcare overseas sales rights and supplying products. As a result, Osang Healthcare will be responsible for the global distribution of DangQLac.

DangQLac is expected to generate significant synergy with Osang Healthcare's main products, which are diagnostic devices for chronic diseases (blood glucose, glycated hemoglobin, cholesterol, etc.), as they share a similar customer base. Although regulatory approval procedures and timelines vary by country, Osang Healthcare is confident that it will achieve meaningful results this year, the first year of operations, through its global distribution network (covering over 100 countries and 140 business partners).

Full article : [Pharmaceutical Newspaper] Yuhan Corporation and Osang Healthcare join hands for global business of 'DangQLac'